Debiotech significantly expands its R&D facilities
by acquiring additional premises in Lausanne.
(June 14, 2002)
In view of its significant growth during the last 12 months, with about 25% new engineers hired for new development projects, Debiotech has acquired a new 550 M2 surface area in its present building location.
This new area will be mostly devoted to new offices and a clean room area for the development of MEMS devices for which Debiotech has presently numerous major developments undergoing. This new area will be used in addition to its present R&D Labs and will almost increase its present R&D capability by 50%.
Dr. Frédéric Neftel, CEO, Debiotech SA, stated, “This new area will enable us to better satisfy our partners’ requirements to complete important new development projects in a state of the art and most efficient way. It is also an investment for future major products in the micro and nano fields where Debiotech has a strong experience and technological advance. It is further a commitment to the Lausanne area where we benefit from a strong R&D environment and support, in particular with EPFL (Swiss Federal Institute of Technology Lausanne) and CHUV (Lausanne University Hospital), which are an integral part of our continuous success in the Medical Device field.”
“This new R&D Labs extension will offer state of the art R&D capabilities and contribute to the continuous improvement of the working environment for our R&D Engineers who deserve a strong consideration for their outstanding work over the recent years”, says Brigitte Neftel, CFO of Debiotech.
The new R&D Labs opening is scheduled for September this year.